GSK completes major three-part transaction with Novartis
02 March 2015
On March 2, 2015 we completed a 3-part transaction with Novartis which reshapes our business.
We acquired Novartis's vaccines business (excluding influenza vaccines) and combined our Consumer Healthcare businesses to create a new company. By substantially strengthening Vaccines and Consumer Healthcare, we can deliver far-reaching benefits to patients and consumers, and further value to shareholders. In addition, Novartis acquired our marketed Oncology portfolio.
Visit the Global Media Centre to read the press release (note: you will be redirected to the global site. Content available in English only).
|Corporate Communications||+1 905-819-3363||(Mississauga)|